Associations of TP53 codon 72 polymorphism with complications and comorbidities in patients with type 1 diabetes.
Adolescent
Alleles
Case-Control Studies
Celiac Disease
/ epidemiology
Child
Codon
/ genetics
Comorbidity
Diabetes Mellitus, Type 1
/ complications
Diabetic Nephropathies
/ epidemiology
Diabetic Retinopathy
/ epidemiology
Dyslipidemias
/ epidemiology
Female
Gene Frequency
Genetic Markers
/ genetics
Genetic Predisposition to Disease
Humans
Hypertension
/ epidemiology
Male
Polymorphism, Genetic
Thyroiditis, Autoimmune
/ epidemiology
Tumor Suppressor Protein p53
/ genetics
Up-Regulation
/ genetics
Diabetes complications
TP53 codon 72 polymorphism
Type 1 diabetes
Journal
Journal of molecular medicine (Berlin, Germany)
ISSN: 1432-1440
Titre abrégé: J Mol Med (Berl)
Pays: Germany
ID NLM: 9504370
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
11
09
2020
accepted:
29
12
2020
revised:
22
12
2020
pubmed:
27
1
2021
medline:
29
1
2022
entrez:
26
1
2021
Statut:
ppublish
Résumé
Wild-type TP53 plays an important role in the regulation of immune response and systemic inflammation. In type 1 diabetes (T1D), TP53 pathways are upregulated and an increased susceptibility to apoptosis is observed. We hypothesize that TP53 codon 72 polymorphism could be associated with complications and comorbidities in patients with T1D. We have investigated the associations of the TP53 codon 72 polymorphism with the T1D complications and comorbidities (retinopathy, nephropathy, hypertension, dyslipidemia, autoimmune thyroiditis, and celiac disease) in 350 patients. The key results of our approach are as follows: (1) In diabetic subjects, the Pro/Pro genotype is associated with an increased risk of microvascular complications, dyslipidemia, and celiac disease; (2) the Arg/Arg variant is associated with a decreased risk of autoimmune thyroiditis and celiac disease; (3) the Pro allele is associated with an increased risk of dyslipidemia, autoimmune thyroiditis, and celiac disease. Although further studies are required, our results for the first time indicate that the TP53 codon 72 polymorphism could be considered a genetic marker to predict the increased susceptibility to some T1D complications and comorbidities. KEY MESSAGES: We analyzed the TP53 codon 72 polymorphism in patients with T1D. Pro/Pro genotype is associated with an increased risk of microvascular complications, dyslipidemia, and celiac disease. The Arg/Arg variant is associated with a decreased risk of autoimmune thyroiditis and celiac disease. The Pro allele is associated with an increased risk of dyslipidemia, autoimmune thyroiditis, and celiac disease.
Identifiants
pubmed: 33495869
doi: 10.1007/s00109-020-02035-1
pii: 10.1007/s00109-020-02035-1
pmc: PMC8055568
doi:
Substances chimiques
Codon
0
Genetic Markers
0
TP53 protein, human
0
Tumor Suppressor Protein p53
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
675-683Références
J Pediatr Endocrinol Metab. 2011;24(7-8):437-9
pubmed: 21932578
Ann Clin Lab Sci. 2001 Jul;31(3):253-8
pubmed: 11508828
Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7605-9
pubmed: 1652755
J Clin Lab Anal. 2008;22(5):321-6
pubmed: 18803266
PLoS One. 2011 Jan 20;6(1):e15813
pubmed: 21283750
Mol Cell Biol. 1999 Feb;19(2):1092-100
pubmed: 9891044
J Pediatr. 2009 Sep;155(3):S6.e15-26
pubmed: 19732566
Clin Chem. 1972 Jun;18(6):499-502
pubmed: 4337382
Diabetes. 2005 May;54(5):1423-8
pubmed: 15855329
FASEB J. 2005 Jun;19(8):1030-2
pubmed: 15811878
Nat Rev Immunol. 2016 Dec;16(12):741-750
pubmed: 27667712
Cell Cycle. 2008 Jan 15;7(2):158-63
pubmed: 18256523
Am J Hum Genet. 2009 Apr;84(4):534-41
pubmed: 19344876
Arch Dis Child. 1990 Aug;65(8):909-11
pubmed: 2205160
Crit Rev Immunol. 2014;34(6):509-16
pubmed: 25597313
Biomed Rep. 2018 Sep;9(3):259-265
pubmed: 30271603
Am Fam Physician. 2000 Feb 15;61(4):1047-52, 1054
pubmed: 10706157
Pediatrics. 2004 Aug;114(2 Suppl 4th Report):555-76
pubmed: 15286277
Ophthalmology. 1991 May;98(5 Suppl):807-22
pubmed: 2062514
Clin J Am Soc Nephrol. 2011 Jun;6(6):1427-35
pubmed: 21566103
Cell Rep. 2016 Mar 15;14(10):2413-25
pubmed: 26947067
Cell Cycle. 2018;17(3):275-276
pubmed: 29265907
Springer Semin Immunopathol. 1998;19(3):345-62
pubmed: 9540161
Acta Diabetol. 2013 Jun;50(3):429-36
pubmed: 23269546
Cell Cycle. 2011 May 1;10(9):1352-5
pubmed: 21566457
FASEB J. 2010 May;24(5):1347-53
pubmed: 20019240
Diabetes Care. 2003 Jul;26(7):2194-7
pubmed: 12832334
J Diabetes. 2015 May;7(3):430-2
pubmed: 25492086
Eur J Endocrinol. 2017 Feb;176(2):133-141
pubmed: 27913607
J Immunol. 2013 Oct 1;191(7):3614-23
pubmed: 24006461
Nature. 2009 Apr 30;458(7242):1127-30
pubmed: 19407794
J Endocrinol Invest. 2015 Nov;38(11):1175-82
pubmed: 25935255
World J Gastroenterol. 2015 Sep 28;21(36):10358-66
pubmed: 26420962
Diabetes Care. 2010 Jan;33 Suppl 1:S62-9
pubmed: 20042775
Nat Rev Cancer. 2009 Oct;9(10):691-700
pubmed: 19759539
Mol Biol (Mosk). 2007 Nov-Dec;41(6):989-93
pubmed: 18318116
PLoS One. 2009 Aug 05;4(8):e6527
pubmed: 19654878
Cell Metab. 2013 Nov 5;18(5):617-33
pubmed: 23954639
Cold Spring Harb Perspect Biol. 2010 May;2(5):a001032
pubmed: 20452958
PLoS One. 2020 Jan 29;15(1):e0228296
pubmed: 31995625
Autoimmunity. 1999;31(4):229-35
pubmed: 10789988